Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

26.64USD
16 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$26.64
Open
$26.90
Day's High
$27.86
Day's Low
$26.53
Volume
50,414
Avg. Vol
77,102
52-wk High
$35.48
52-wk Low
$21.27

Latest Key Developments (Source: Significant Developments)

Theravance Biopharma To Reduce Overall Headcount By About 50 Individuals
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA ANNOUNCES ALIGNMENT OF WORKFORCE WITH FOCUS ON KEY STRATEGIC PRIORITIES.THERAVANCE BIOPHARMA INC - THERAVANCE BIOPHARMA WILL REDUCE ITS OVERALL HEADCOUNT BY APPROXIMATELY 50 INDIVIDUALS.THERAVANCE BIOPHARMA INC - EMPLOYEES AFFECTED BY HEADCOUNT REDUCTIONS PRIMARILY FOCUSED ON EARLY RESEARCH OR INFRASTRUCTURE IN SUPPORT OF VIBATIV.  Full Article

Theravance, Mylan Expect YUPELRI To Be Available To U.S. COPD Patients Before End Of The Year
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA AND MYLAN RECEIVE FDA APPROVAL FOR YUPELRI™ (REVEFENACIN) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.THERAVANCE BIOPHARMA INC - CO, MYLAN EXPECT YUPELRI TO BE AVAILABLE TO COPD PATIENTS IN U.S. BEFORE END OF THE YEAR.  Full Article

FDA Approves Theravance Biopharma's COPD Drug Yupelri
Friday, 9 Nov 2018 

Nov 9 (Reuters) - U.S. Food And Drug Administration::U.S. FDA - APPROVES THERAVANCE BIOPHARMA'S COPD DRUG YUPELRI.  Full Article

Theravance Biopharma Says Renee Gala Resigns As CFO
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA SAYS ON OCT 3, RENEE D. GALA NOTIFIED CO OF HER RESIGNATION AS CHIEF FINANCIAL OFFICER EFFECTIVE ON JANUARY 2, 2019 - SEC FILING.  Full Article

Theravance Biopharma Reports Qtrly Loss Per Share $0.76
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA, INC. REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.THERAVANCE BIOPHARMA INC - QTRLY LOSS PER SHARE $0.76.THERAVANCE BIOPHARMA INC - QTRLY TOTAL REVENUE $23.5 MILLION VERSUS $3.5 MILLION.THERAVANCE BIOPHARMA - GUIDANCE ON OPERATING LOSS EXCLUDING NON-CASH SHARE-BASED COMPENSATION FOR FY REMAINS UNCHANGED.  Full Article

Theravance Biopharma Reports Positive Top-Line Four-Week Data From Phase 2 Trial Of Td-9855
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA REPORTS POSITIVE TOP-LINE FOUR-WEEK DATA FROM PHASE 2 TRIAL OF TD-9855 FOR THE TREATMENT OF SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION.THERAVANCE BIOPHARMA INC - THERE WERE NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED, AND TD-9855 WAS GENERALLY WELL TOLERATED IN STUDY.THERAVANCE - CONCLUDED DISCUSSIONS WITH FDA ON DESIGN OF PIVOTAL PHASE 3 REGISTRATIONAL PROGRAM, TO INITIATE PROGRAM IN LATE 2018 OR EARLY 2019.  Full Article

Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA.THERAVANCE BIOPHARMA INC - ‍FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH U.S. FDA FOR USE OF TRELEGY ELLIPTA​.  Full Article

Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Theravance Biopharma Inc -:Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease.Theravance Biopharma Inc - ‍NDA is supported by companies' Phase 3 program for revefenacin​.  Full Article

Theravance Biopharma posts Q3 loss of $1.27 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Theravance Biopharma Inc :Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update.Q3 revenue $4.3 million versus i/b/e/s view $4.6 million.Cash, cash equivalents and marketable securities, excluding restricted cash, totaled $434.4 million as of september 30, 2017​.Qtrly basic and diluted net loss per share $1.27‍​.  Full Article

Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Mylan Nv :Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting.Theravance Biopharma Inc - ‍remain on track to submit an NDA for Revefenacin Q4 of 2017​.Theravance Biopharma Inc - ‍results demonstrated statistically significant and clinically meaningful improvements for revefenacin over placebo ​.Theravance Biopharma Inc - ‍both doses of revefenacin had comparable rates of adverse events to placebo​.  Full Article

UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.